ClinicalTrials.gg
CompletedNCT02437604Updated Nov 9, 2021

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

A Phase 1 interventional study of Treatment A: Fp MDPI and Treatment B: FS MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 3 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
96th of 146
43 · median 100
Started
2015
with 6 others
Phase 1
22 of 147
none open now
Registered
111th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 96th largest by enrollment of the 146 interventional ones that give a count, is one of 7 that started in 2015, is one of 22 in phase 1, and was the 111th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

Each patient will participate in the study for approximately 7 weeks. Participation will include a screening period of up to 21 days and 4 treatment periods; each consisting of a 3-day/2-night inpatient period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Criteria: • Inclusion Criteria:
  • The patient has persistent asthma.
  • To meet current asthma therapy requirements patients must be currently treated with inhaled (ICSs) at a dose that has been stable for at least 30 days before the SV.
  • Written /assent is obtained. For adult patients (aged 18 years and older, or as applicable per local regulations), the written ICF must be signed and dated by the patient before conducting any study-related procedure. For minor patients (aged 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable) before conducting any study related procedure. Note: Age requirements are as specified by local regulations.
  • The patient is a male or female 12 years of age or older, as of the visit when the ICF/assent form is signed (SV).
  • Asthma diagnosis: The patient has a diagnosis of asthma as defined by the NIH. The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in asthma medication) for at least 30 days before providing informed consent.
  • The patient is able to demonstrate acceptable and reproducible inhalation technique with the DISKUS device and the Teva MDPI device.
  • The patient is able to withhold (as judged by the investigator) his or her rescue medication for at least 6 hours before the SV and before all treatment visits where spirometry is performed.
  • The patient has a (BMI = weight [kg] ÷ height2 [m]) within the 5th and 97thpercentiles for the patient's age and gender. The patient must have a weight of 115 pounds or higher.
  • The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (eg, dose schedules, visit schedules, blood draws, procedures, and record keeping).

    • Other criteria may apply, please contact the investigator for more information.
  • Exclusion Criteria:
  • The patient has a history of a life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures.
  • The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the patient's last study-related visit (for eligible patients only, if applicable). Eligible female patients unwilling to employ appropriate measures to ensure that pregnancy will not occur during the study will be excluded. Any patient becoming pregnant during the study will be withdrawn from the study.
  • The patient has participated as a randomized patient in any drug study within 30 days (starting from the final follow-up visit of that study) preceding the SV or plans to participate in another investigational drug study at any time during this study.
  • The patient has previously participated in an Fp MDPI or FS MDPI study. Participation is defined as randomization to treatment.
  • The patient has a known to any corticosteroid, salmeterol, or any of the in the study drug (ie, lactose).
  • The patient has been treated with any known cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV or plans to be treated with any inhibitor during the study.The patient has been treated with any of the prohibited medications during the prescribed (per protocol) before the SV.
  • The patient has either lost or donated ≥500 mL of whole blood within the 60 days before the first dose of study drug or the patient has received or donated plasma, white blood cells, or within the 14 days before the first dose of study drug. Patients that have plans to donate blood or blood products during the study or within the 90 days after completion of the study are also excluded.
  • The patient currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  • The patient has a culture-documented or suspected bacterial or viral upper respiratory tract infection (URTI) or lower respiratory tract infection (LRTI),
  • The patient has a history of alcohol or drug abuse within 2 years preceding the SV.
  • The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV.
  • The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study. Note: Azole antifungals are prohibited.
  • The patient is either an employee or an immediate relative of an employee of the investigational center.
  • A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened.
  • The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

    • Other criteria may apply, please contact the investigator for more information.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Treatment A

    Fp MDPI 200 mcg, 1 inhalation

    Drug: Treatment A: Fp MDPI

  • Experimental
    Treatment B

    FS MDPI 200/12.5 mcg, 1 inhalation

    Drug: Treatment B: FS MDPI

  • Active comparator
    Treatment C

    fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations

    Drug: Treatment C Flovent

  • Active comparator
    Treatment D

    fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation

    Drug: Treatment D: Advair

Interventions

  • Fp MDPI 200 mcg, 1 inhalation

    Also known as: fluticasone propionate

  • DrugTreatment B: FS MDPI

    Drug pages: Fluticasone · Salmeterol Xinafoate

    FS MDPI 200/12.5 mcg, 1 inhalation

    Also known as: fluticasone propionate/salmeterol

  • FLOVENT DISKUS 250 mcg, 2 inhalations

    Also known as: fluticasone propionate

  • DrugTreatment D: Advair

    ADVAIR DISKUS 500/50 mcg, 1 inhalation

    Also known as: fluticasone propionate/salmeterol

06

What researchers measure

Primary outcomes

  1. AUC0-t Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours After administration

  2. Cmax Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours After administration

Secondary outcomes

  1. AUC0-∞ Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  2. AUC%extrap Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  3. tmax Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  4. t½ Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  5. λz Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  6. CL/F Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

  7. Vz/F Plasma drug concentration

    Time frame: 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 16, 24, 30, and 36 hours after administration

07

Study locations

3 sites
  • Teva Investigational Site 13178
    Raleigh, North Carolina, United States
  • Teva Investigational Site 13177
    Edmond, Oklahoma, United States
  • Teva Investigational Site 13179
    San Antonio, Texas, United States
08

References and documents

Publications

  • Nugent C, Yiu G, Song S, Caracta C. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma. J Asthma. 2018 Aug;55(8):898-906. doi: 10.1080/02770903.2017.1373392. Epub 2017 Oct 30. PubMed 28933971 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jul 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2015
First posted
May 7, 2015
Start
May 2015
Primary completionActual
Jul 2015
CompletionActual
Sep 2015
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02437604
Responsible party
Sponsor
First posted
May 7, 2015
Start date
May 2015
Primary completion
Jul 2015
Completion
Sep 2015
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion